Novo Nordisk pipeline:Novo Nordisk
Novo Nordisk
ada-investor
https://www.novonordisk.com
Strengthen and progress the Rare disease pipeline. • Establish presence in Other serious chronic diseases focusing on CVD, NASH and CKD.
Cell therapy
https://www.novonordisk.com
Novo Nordisk is focused on developing and delivering transformative cell therapies with a goal to reduce the global burden of disease, empowering individuals ...
Novo Nordisk bets $1B on biotech buyout to grow obesity ...
https://www.fiercebiotech.com
Novo Nordisk inked a deal worth up to $1.1 billion to buy a biotech ... Canadian biotech buyout, adding an old approach to obesity pipeline.
Novo Nordisk
https://www.novonordisk.com
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and ...
Our medicines
https://www.novonordisk.com
Overview of our diabetes medications, obesity medication and also medicines within haemophilia, human growth hormone and hormone replacement therapy.
Pipeline
https://www.formatherapeutics.
Our pipeline consists of product candidates in multiple disease areas, including sickle cell, thalassemia and prostate cancer. Pipeline.
Pipeline Moves
https://www.clinicaltrialsaren
Novo Nordisk's injectable semaglutide is currently marketed as Ozempic for use as an adjunct to diet and exercise to improve glycemic control ...
R&D pipeline
https://www.novonordisk.com
At Novo Nordisk, our R&D pipeline reflects our long-standing commitment to driving change to defeat diabetes and other serious chronic conditions.